The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

19 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
41
Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.EBI
Janssen Research and Development
100
1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.EBI
Merck Research Laboratories
24
Lysine demethylases inhibitors.EBI
Kyoto Prefectural University of Medicine
8
Structural basis for binding of cyclic 2-oxoglutarate analogues to factor-inhibiting hypoxia-inducible factor.EBI
University of Oxford
15
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.EBI
Nagoya City University
91
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.EBI
University College London
6
Novel Compounds as PHD Inhibitors for Treating Heart, Lung, Liver, and Kidney Diseases.EBI
Smith, Gambrell & Russell
27
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.EBI
Merck Research Laboratories
1
Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.EBI
Oxford University
27
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.EBI
Merck
32
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.EBI
Cadila Healthcare
66
1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.EBI
Takeda California
60
Methods of inhibiting formation of alpha synuclein aggregatesBDB
University of California
71
Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancerBDB
Korea Research Institute of Chemical Technology
16
ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOFBDB
Bolt Biotherapeutics
58
Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereofBDB
Debiopharm International
10
Fused cyclopentyl antagonists of CCR2BDB
Janssen Pharmaceutica